InsiderTrades.com logo

ACOR Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 2.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Acorda Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Acorda Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acorda Therapeutics Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 04/11/2024 05:00 PM ET

This chart shows the closing price history over time for ACOR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Acorda Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2023Ron CohenCEOBuy507$12.00$6,084.006,987View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Acorda Therapeutics (NASDAQ:ACOR)

12.71% of Acorda Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACOR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Acorda Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/7/2023Acadian Asset Management LLC34,131$0.44M0.0%-95.0%2.798%Search for SEC Filing on Google Icon
2/10/2022Acadian Asset Management LLC467,739$1.12M0.0%+22.3%4.175%Search for SEC Filing on Google Icon
11/15/2021Point72 Asset Management L.P.468,166$2.15M0.0%-47.3%4.209%Search for SEC Filing on Google Icon
11/12/2021Renaissance Technologies LLC724,718$3.33M0.0%+1.5%6.515%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.161,939$0.74M0.0%-3.2%1.456%Search for SEC Filing on Google Icon
11/1/2021AE Wealth Management LLC40,457$0.19M0.0%N/A0.364%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Acorda Therapeutics logo
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Read More on Acorda Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: $9.68
Low: $0.66
High: $15.60

52 Week Range

Now: N/A

Volume

416,900 shs

Average Volume

119,299 shs

Market Capitalization

$820 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4